Top Story

HPV vaccine offers multisite protection, even among previously exposed women

HPV vaccine offers multisite protection, even among previously exposed women
April 21, 2015

Read the Perspective from Miriam Lango, MD

PHILADELPHIA — HPV vaccination of women aged 18 to 25 years provides strong combined protection against HPV 16/18 infection at three anatomical sites among those with and without prior HPV exposure, according to study findings presented at the American Association for Cancer Research Annual Meeting.

Previous data from the Costa Rica Vaccine Trial demonstrated strong efficacy against HPV 16/18 at the cervical, anal and oral regions separately, according to study background. However, the combined efficacy of infections at all three anatomic sites had not previously been measured in women with or without prior HPV 16/18 exposure.

Carole Fakhry, MD, MPH In the Journals

Surgical salvage improves OS in recurrent metastatic OPSCC

April 21, 2015
Surgical salvage was associated with prolonged OS in patients with recurrent locoregional or distant metastatic oropharyngeal squamous cell carcinoma regardless of HPV…
Meeting News Coverage

Greater understanding of resistance mechanisms needed in basal cell carcinoma

April 21, 2015
NEW YORK — Hedgehog inhibitors have demonstrated high activity and durability in patients with advanced basal cell carcinoma, and they also possess a predictable…
Meeting News CoveragePerspective

Breast cancer incidence will increase by 50% by 2030

April 21, 2015
PHILADELPHIA — The total number of invasive and in-situ breast cancer cases in the United States likely will increase 50% by 2030, according to study results…
Meeting News CoveragePerspective

MPDL3280A shows promise in metastatic triple-negative breast cancer

April 20, 2015
PHILADELPHIA — The investigational immunotherapy MPDL3280A appeared well tolerated and demonstrated favorable efficacy in patients with metastatic triple-negative…
More News Headlines »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

April 12, 2015
Robert O. Dillman, MD, vice president of oncology at NeoStem Inc., provides an overview of a phase 3 trial evaluating…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »